Analysis on post-marketing effectiveness and immunogenicity of enterovirus-A71 vaccine
10.3760/cma.j.cn112338-20191006-00717
- VernacularTitle:肠道病毒71型疫苗上市后疫苗保护效果和免疫原性分析
- Author:
Ruijue HUA
1
;
Jin HUANG
;
Xiaojuan ZHANG
;
Qi SHEN
;
Mingyi CAI
;
Feng YUAN
;
Ying ZHANG
;
Pingfang CUI
;
Ying LI
;
Haoyu SHI
;
Biao XU
Author Information
1. 上海市静安区疾病预防控制中心 200072；复旦大学公共卫生学院，上海 200032
- Keywords:
EV-A71 vaccine;
Hand, foot, and mouth disease;
Effectiveness;
Immunogenicity
- From:
Chinese Journal of Epidemiology
2020;41(9):1518-1521
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To analyze the effectiveness and immunogenicity of enterovirus-A71(EV-A71) vaccine in immunization program.Methods:A cohort study was conducted in immunization clinics in Jing’an district in Shanghai from October to December 2017. Children who received EV-A71 vaccine based on a 2-dose schedule (on day 0 and day 30) were enrolled as vaccine group and those who received no EV-A71 vaccine were enrolled as control group. After 1-year follow-up, the effectiveness and neutralizing antibody level and the positive results of antibody immunogenicity in vaccine group were analyzed.Results:A total of 3 018 children aged 8-20 months were enrolled, in whom 1 211 were in vaccine group and 1 807 were in control group. The vaccine effectiveness was 100% against EV-A71-associated hand, foot, and mouth disease (HFMD) indicated by 1 year follow-up (95 %CI: -66.99%-100.00%). The geometric mean titer of neutralizing antibody (GMT) was 41.76 (95 %CI: 35.60-49.34) at day 60 and 28.44(95 %CI: 23.59-34.54) at day 365 in 124 children in vaccine group. Conclusions:In children, EV-A71 vaccine elicited EV-A71-specific immune response. Less EV-A71-associated HFMD cases have been observed, further observation is needed.
